This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
From AI models that boost sales to robots that slash production costs, advanced technologies are transforming both top-line growth and bottom-line efficiency. Business leaders dont need to be technology experts to grasp this shift; they need vision and urgency. The path from lab to market keeps shortening.
startups raised half a billion dollars apiece, and another eight raised $100 million or more, with industries from cybersecurity to biotech to AI represented. tied) Insider , $500M, digital marketing: Marketing tech platform Insider raised a $500 million Series E led by General Atlantic to fund its expansion in the U.S.
2021 should be a banner year for biotech startups that make smart choices early. After a record year for biotech investment in 2020 — during which the industry saw $28.5 billion invested across 1,073 deals — the market for new innovations remains strong. More posts by this contributor. Kevin O’Connor. Contributor.
James Coates is the Health and Human Performance principal at Decisive Point , a venture capital and advisory firm that invests in and supports startups with emerging defense technologies. Inflationary market dynamics and ongoing fiscal tightening continue to pose significant risks to capital commitments.
Given this success, many biotech companies are looking to move on to the next phase of their organizational growth — which may mean an initial public offering. As optimism grows, market conditions may stabilize in 2025 — particularly in the wake of the recent interest rate cuts — and more biotech companies may consider offerings.
That’s why we weren’t very surprised when a slew of investors told us they rarely see a biotech startup that doesn’t incorporate AI in some form or other these days. But despite becoming quite the buzzword, AI’s apparent ubiquity in biotech isn’t actually driving deal flow or higher valuations.
tech unicorns made it to market. Biotech offerings, while more plentiful, are also running well below prior highs. Below, we pick out winners and losers for venture-backed tech and biotech companies, focusing on large- and medium-sized IPOs. footnote]since the companys March IPO , delivering a market cap around $26 billion.
Marketing and personalization startup Hightouch locked up an $80 million Series C led by Sapphire Ventures , minting it as a new unicorn at a $1.2 Hightouchs AI Decisioning product allows marketers to synchronize data and then let AI agents decide what messages and/or experiences to send each customer personalizing the marketing effort.
Although 2024 was another exceptionally lackluster year for new public offerings, the IPO market could gain momentum in 2025 after its three-year lull. With that in mind, here are 13 companies that the Crunchbase News team thinks could be top contenders to go public if our 2025 market forecast bears out. That made sense.
Stämm Biotech , founded in 2014, is developing a desktop-sized bioreactor that looks pretty different from the tanks, tubes and knobs traditionally seen in industrial or even benchtop bioreactors. Image Credits: Stämm Biotech. And, as of writing, Ginkgo’s market cap was closer to $7.24 Image Credits: Stämm Biotech.
Just some of the core competencies you need to lock down include how to raise VC funding, recruiting the right people, finding product-market fit and building a killer go-to-market team. Are you inspired to use biology as technology? The list goes on and on…and on. Do you science?
With the constant advancements in technology and research, businesses in this sector require leaders who possess a deep understanding of the scientific landscape and the business acumen to drive growth and innovation. The life sciences industry is known for its unique challenges in recruiting and hiring.
Biotech can often, and sometimes literally, fly over our heads. For IndieBio, a science and biotech accelerator run by VC firm SOSV, this unprecedented year offered high stakes and new challenges. Today and tomorrow, the biotech accelerator is hosting its twice-annual demo day. Image Credits: Witthaya Prasongsin / Getty Images.
“As your technology becomes more dated, you too will have to make similar decisions.” “Gogoro will use the fresh funds from its IPO to continue to expand in Taiwan as it branches outward to larger markets like China, India and Indonesia,” writes transportation reporter Rebecca Bellan. Walter Thompson.
Even so, investment remains below the heights scaled during the 2021 market peak. Its stock has performed well, with shares up several-fold and a recent market cap around $11 billion. Funding at the intersection of healthcare and AI has been on a tear this past year. Last year, more than $7.5
By Caleb Appleton Having invested in the biotech space since before it had a name, Ive seen life sciences investors steer founders toward a therapeutics pipeline in hopes of securing the payout of a winning drug or medical device. Does the market see value in the tool today, or do you need to educate? What is your superpower?
Sifting through the trillions of molecules out there that might have powerful medicinal effects is a daunting task, but the solution biotech has found is to work smarter, not harder. Machine learning has, of course, accelerated work in many fields, biochemistry among them, but he felt that the potential of the technology had not been tapped.
A new nanocoating from Curran Biotech could dramatically improve air filtration to prevent the spread of COVID-19 indoors. Their Capture Coating technology acts as a supplement to any household or commercial HVAC system by bonding to the filter fibers , giving them greater hydrophobic properties.
Protein biochemist Dr. Jasmin Hume was working in the alternative food space when she saw an opportunity to evolve technology so that our global food industry can reduce its reliance on animals. Both the food ingredients and plant-based proteins markets are poised for steady growth.
funding market raised a greater proportion of global funding, up from 48% in 2023. Large early-stage rounds went to data centers, renewable energy, AI, robotics and biotech. An opening up of the IPO markets in 2025 will drive LP allocation to venture, said Beezer Clarkson , a partner at Sapphire Ventures , in an interview.
.” A more favorable regulatory and social landscape is helping psychedelic startups gain a foothold, but they still have to walk a tightrope that’s susceptible to the vagaries of market sentiment. But as public market sentiment fluctuates, specialized VCs seem more likely to stick around for the whole trip. Ready for the trip?
But Locus Biosciences is hoping that their crPhage technology might provide a new solution. Led in part by former Patheon executive and current Locus CEO Paul Garofolo, the startup launched in 2015 with the goal of using a less popular application of CRISPR technology to address growing antimicrobial resistance.
The week was especially good for biotech, which led the way with two big raises. Tome Biosciences , $213M, biotech: A big biotech raise hit high on the list this week. Bicara Therapeutics , $165M, biotech: If Bicara Therapeutics looks familiar, it’s because this isn’t its first time on this list.
Of course, biotech and fintech were in there too. tied) Serán Bioscience , $200M, biotech : The big biotech raise this week went to Serán Bioscience. Air Company , $69M, greentech: New York-based Air Company, a carbon conversion technology company, raised a $69 million Series B led by Avfuel.
When I started at Novanta about five years ago, my first mission was to bring scalability to our Enterprise solutions, as well as developing a digital roadmap to modernize the technology footprint, reduce technical debt, and explore strategies to ensure that we’re growing at scale. We need more women in technology.
Zero-based budgeting: A proven framework for extending runway 5 strategies for biotech startups to outlast a market downturn Image Credits: Getty Images Spinning up a biotech company is a massive undertaking.
Lifebit says it has a patented technology for federating the data around genomic data, allowing researchers to get more insights while keeping the data secure. In an increasingly hot biotechmarket, protecting IP is key. Privacy issues are regularly raised around genomic data.
Other fungicides on the market today require seven days before re-entry and pre-harvest, Uknes explained. His firm has an impact fund focused on the future of food and began investing in alternative proteins in 2016 before expanding that to delivery systems in agriculture technology, he said.
This morning private-market powerhouse Andreessen Horowitz announced that it has closed $9 billion in new capital for its venture capital, growth-stage and biotech-focused vehicles. As an investing collective, a16z, like many private-market investors, is putting more capital to work per new crop of new funds. remains red-hot.
We mainly invest in SaaS companies with some proven traction in the market – but overall, we seek the best technology entrepreneurs that want to make an impact. Our focus is on entrepreneurial and technological initiatives aimed at digitalizing and increasing the productivity of traditionally undigitized sectors.
“We added fermentation/biotechtechnologies to enhance taste and texture,” wrote CEO and co-founder Christoph Jenny in an email to TechCrunch. The company plans to enter several new markets over Q3 and Q4, but the U.S. Over time the process has improved as well.
The competition is not your market competitor or incumbent. More often, it is the investor’s set of operating heuristics, many of which are quickly influenced by market conditions. When markets start to dip, most companies hunker down and focus on surviving. Reframe the macro view. Get granular.
The hearing loss market has long been dominated by a handful of legacy players with little incentive to innovate due to outdated regulations and social stigma. Food and Drug Administration could revolutionize the market by driving competition, giving startups a greater chance at success in this sector. But a new ruling from the U.S.
At TechCrunch Early Stage: Marketing and Fundraising, two experienced investors spoke on the subject and advised startups facing a challenging fundraising path. Pae Wu and Garrett Winther are both partners at SOSV and run the fund’s programs around biotech and hardware. Set obtainable goals.
According to a statement, the company will invest heavily in developing new manufacturing technologies across cell and gene therapies, viral vectors, vaccines and proteins. billion to spend on sustainability and health-focused biotech. “It Flagship Pioneering raises $1.1
While we’re still far away from achieving that lofty goal, science has advanced a lot and as life expectancy increased, longevity is now a realm of technology and medicine that aims to increase how long people can live healthily. Analysts estimate that the market for delaying human death could be worth $610 billion by 2025.
It is associated with The University of Tokyo (UTokyo), where it has a partnership with its Technology Licensing Office (TLO) to spin off and invest in companies that originated as research projects. Broadly speaking, UTEC focuses on three areas: healthcare and life sciences, information technology and physical sciences and engineering.
As the global startup market digests a changing valuation environment and climate for venture investment, not every sector is taking the same amount of damage. Instead, it’s the tried-and-true software-as-a-service (SaaS) category that appears to be in the best shape to fend off a slowdown in private-market investment.
The life sciences industry is characterized by unique challenges and complexities, requiring leaders who deeply understand scientific advancements, regulatory frameworks, and highly dynamic market conditions.
Gingko’s market debut is one of the largest in biotech history. each this morning under the ticker DNA — biotech dieharders will recognize it as the former ticker used by Genentech. . I cannot predict when Roche might bring a drug to market and give me my milestones,” says Kelly. . It’s expected to raise about $1.6
Respira Labs , a medical technology company specializing in respiratory care, which first unveiled its product to the world last year , successfully raised $1 million in funding and an additional $1.8 million in grants to continue building its acoustic resonance technology to assess lung function and changes therein.
Clean tech – Tied in with the biotech trend, we’re seeing a continued surge in input/output companies that process waste to produce byproducts like energy and potable water. market is terrible at taking care of elderly and infirm people, in general. The robotics, AI and biotech sectors all play a part here.
Combining his experience as an operator and institutional investor, Abelson runs Irving as a multistrategy platform making long-term durable investments in both the public and private markets. Jacob Sonnenberg is a portfolio manager at Irving Investors and runs Irving's Technology and Consumer Crossover Fund. What am I worth now?
UMI’s decision to invest in Boost comes from our evaluation of their team, technology, and the associated market opportunities. Boost is already working with an undisclosed biomanufacturing partner to develop its bio-fungicide. “These are critical areas to achieve food security and promote sustainable agriculture.
We organize all of the trending information in your field so you don't have to. Join 49,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content